Petros Pharmaceuticals Inc (PTPI) USD0.0001
$0.0206
(7.15%)
- Add to watchlist
- This stock can be held in a
$0.0206
(7.15%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.0206
(7.15%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. It also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
Contact details
Important dates
General stock information
- Short code:
- PTPI
- ISIN:
- US71678J2096
- Market cap:
- $2.89 million
- Shares in issue:
- 10.01 million
- Sector:
- Pharmaceuticals
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.